New York, March 06, 2023 (GLOBE NEWSWIRE) -- According to The Insight Partners, “Respiratory Inhalers Market Size, Share, Growth, Trends and Global Forecast to 2028 - COVID-19 Impact and Global Analysis By Product Type [Nebulizers, Metered Dose Inhalers (MDI), and Dry Powder Inhalers], Technology (Manually Operated Inhalers and Digitally Operated Inhalers), and Disease Indication (Asthma, COPD, Pulmonary Arterial Hypertension, and Others)” the global respiratory inhalers market growth is driven by rising cases of respiratory disorders, growing adoption of generic inhalers and increasing adoption of smart inhalers technology.
Download PDF Brochure at https://www.theinsightpartners.com/sample/TIPRE00003093
Global Respiratory Inhalers Market – Report Scope:
| Market Size Value in | USD 31.14 Billion in 2022 |
| Market Size Value by | USD 43.44 Billion by 2028 |
| Growth rate | CAGR of 5.7% from 2022 to 2028 |
| Forecast Period | 2022-2028 |
| Base Year | 2022 |
| No. of Pages | 254 |
| No. of Tables | 165 |
| No. of Charts & Figures | 77 |
| Historical data available | Yes |
| Segments covered | Product Type, Technology, and Disease Indication |
Global Respiratory Inhalers Market Analysis: Competitive Landscape and Key Developments
AstraZeneca Plc; Beximco Pharmaceuticals Ltd.; Boehringer Ingelheim International GmbH; Cipla Ltd.; GSK Plc; Koninklijke Philips NV; OMRON Corp; PARI Respiratory Equipment, Inc.; Teva Pharmaceutical Industries Ltd.; and OPKO Health, Inc. are a few of the key companies operating in the respiratory inhalers market. The market leaders focus on new product launches, expansion and diversification, and acquisition strategies, which allow them to access prevailing business opportunities.
In January 2023, FDA approved Airsupra [pressurized metered-dose inhaler (pMDI)], manufactured by AstraZeneca Plc, in the US for the as-needed treatment or prevention of bronchoconstriction. Airsupra is a first-in-class, pressurized metered-dose inhaler (pMDI), fixed-dose combination rescue medication containing albuterol, a short-acting beta2-agonist (SABA), and budesonide, an anti-inflammatory inhaled corticosteroid (ICS) in the US.
In September 2022, Beximco Pharmaceuticals launched ONRIVA TRIO BEXICAP, which is a dry inhaler capsule. ONRIVA TRIO BEXICAP is the preparation of Indacaterol (150 µg), Glycopyrronium (50 µg), and Mometasone (160 µg). It controls asthma symptoms in three ways. Indacaterol and Glycopyrronium help the muscles of lung airways to stay relaxed to prevent bronchoconstriction, while Mometasone helps to decrease inflammation. ONRIVA TRIO BEXICAP is indicated as maintenance therapy in severe persistent asthma.
In January 2021, Fluticasone Propionate and Salmeterol (‘FPSM’) Dry Powder Inhaler 100mcg, 250mcg was launched. The product contain fluticasone propionate and salmeterol (as xinafoate), which have different modes of action. Salmeterol provides symptomatic relief, while fluticasone propionate improves lung function and prevents exacerbations of the condition. Fluticasone propionate/Salmeterol can offer a more convenient regimen for patients on concurrent long-acting beta-agonist and inhaled corticosteroid therapy.
Inquiry Before Purchase: https://www.theinsightpartners.com/inquiry/TIPRE00003093
Increasing Adoption of Smart Inhalers Technologies Provides Lucrative Opportunities for Global Respiratory Inhalers Market Growth:
Smart inhalers ensure that people suffering from asthma take their medication as prescribed by recording the timing and dosage on their smartphones. The data collected can be used by a clinician to verify that the prescribed treatment is working, personalize asthma reviews to focus on the root causes of worsening symptoms, and provide early warning systems that inform when to visit a clinic. This technology could shift from one-size-fits-all asthma screening and lead to fewer routine appointments, which could ease pressure on the National Health Service (NHS). Smart inhalers benefit adults and the geriatric population, as they struggle to take the same puffs due to uneven breathing as the muscles that support breathing and the diaphragm weaken with age, preventing air from inhaling or exhaling. Smart inhalers that are equipped with sensors can be connected to conventional inhalers and help to keep track of when the medication is taken. Being Bluetooth-enabled, they can also be remotely paired with a computer or smart device, such as a phone or tablet, to transfer data from the smart inhaler automatically. In India, the demand for smart inhalers has increased due to the rising prevalence of respiratory diseases, such as asthma and COPD, and smoking habits. According to the University of Washington's 2018 Global Burden of Disease study, COPD was India's second leading cause of death, resulting in ~958,000. In addition, according to the Tobacco Atlas, more than 625,000 children between the ages of 10 and 14 and 1 billion adults over the age of 15 use tobacco every day in India. Therefore, the above-mentioned applications of smart inhalers and their growing adoption are expected to provide growth opportunities to the respiratory inhalers market in the coming years.
Check Discount on this Report at https://www.theinsightpartners.com/discount/TIPRE00003093
The US holds a significant market share of the respiratory inhalers market. Asthma and chronic obstructive pulmonary disease (COPD) are major health burdens in the US. Asthma is a chronic inflammatory disorder due to airway narrowing and obstruction. COPD is due to obstruction of airflow from the lungs, which causes chronic inflammatory lung disease. Smoking is the main cause of COPD in the US. According to the Centers for Disease Control and Prevention (CDC), in 2020, ~5.0% of adults were diagnosed with COPD, emphysema, or chronic bronchitis in the US. Approximately 25 million people were affected by asthma, and ~14.8 million had COPD in 2020. COPD was the fourth leading cause of death in the US in 2018. Furthermore, ~1 in every 10 infants born in 2020 were preterm births. Thus, the growing prevalence of chronic respiratory disorders and preterm births in the US is driving the respiratory inhalers market. In addition, according to Administration for Community Living, in 2019, the population aged 65 years and above in the US was ~54.1 million, contributing to 16% of the total population. It is expected to reach 21.6% by 2040. The older population is more susceptible to various chronic respiratory diseases. Thus, a continuous rise in the older population is expected to boost the growth of the respiratory inhalers market during the forecast period.
Global Respiratory Inhalers Market: Segmental Overview
Based on product type, the respiratory inhalers market is segmented nebulizers, metered dose inhalers (MDI), and dry powder inhalers. The dry powder inhalers segment is further bifurcated into multi-dose dry powder inhalers and single-dose dry powder inhalers. The metered dose inhalers (MDI) segment is further divided into pressured metered dose inhalers and connected metered dose inhalers. The nebulizers segment is subsegmented into compressed air nebulizers, mesh air nebulizers, and ultrasonic air nebulizers. In 2022, the dry powder inhalers segment accounted for the largest market share. However, the metered dose inhalers (MDI) segment is anticipated to register the highest CAGR during the forecast period. Based on technology, the respiratory inhalers market is bifurcated into manually operated inhalers and digitally operated inhalers. The manually operated inhalers segment held a larger share of the market in 2022 and is expected to register a higher CAGR during the forecast period. Based on disease indication, the respiratory inhalers market is segmented into asthma, COPD, pulmonary arterial hypertension, and others. The asthma segment held the largest share of the market in 2022 and is expected to grow at the highest CAGR during the forecast period.
Buy Premium Copy of Respiratory Inhalers Market Growth Report (2022-2028) at: https://www.theinsightpartners.com/buy/TIPRE00003093
Browse other research published by The Insight Partners:
Global Inhalers Market Size Forecast to 2028 - COVID-19 Impact and Global Analysis By Devices (Metered Dose Inhalers, Dry Powder Inhalers, Nebulizers, Nasal Inhalers); Type (Preventive Inhalers, Reliever Inhalers, Long Acting Bronchodilators Inhalers); Application (Asthma, Chronic Obstructive Pulmonary Diseases, Others); End User (Home Care, Hospitals and Clinics, Others)
Global Smart Inhalers Market Size to 2027 - Global Analysis and Forecasts By Product (Nebulizers and Inhalers); Disorder (Chronic Obstructive Pulmonary Disease (COPD) and Asthma); End User (Home-Care Settings and Hospitals & Clinics) and Geography
Global Medical Inhaler Market Size Forecast to 2028 - COVID-19 Impact and Global Analysis By Product (Dry Powder Inhaler, Metered Dose Inhaler, Others); Application (Asthma, Chronic Obstructive Pulmonary Disorder, Others); End User (Hospitals, Clinics, Respiratory Care Center, Others) and Geography
Global Digital Dose Inhalers Market Size Forecast to 2028 - Covid-19 Impact and Global Analysis - By Product Type ( Metered Dose Inhalers, Dry Powder Inhalers ); Application ( Asthma, COPD, Cystic Fibrosis, Others ) and Geography
Global Breath Actuated Inhalers Market Size Forecast to 2028 - COVID-19 Impact and Global Analysis By Type (Single Dose, and Multi Dose); Application (Asthma, COPD, and Others), and Geography
Global Asthma Inhaler Device Market Size Forecast to 2028 - Covid-19 Impact and Global Analysis - by Type (Metered Dose inhaler, MDI with a spacer, Dry Powder inhaler, Others.); Technology (Manually operated inhaler, Digitally operated inhaler); End User (Hospitals, Clinics, Research Institutes, Others.)
Global Soft Mist Inhalers Market Size Forecast to 2028 - COVID-19 Impact and Global Analysis By Application (COPD, Asthma); End User (Hospitals, Clinics, Others) and Geography
Global Budesonide Inhalers Market Size Forecast to 2028 - Covid-19 Impact and Global Analysis - By Product Type (Inhalants, Nebulizers); Dosage (Aerosols, Dry Powder, Suspension, Spray); Distributional Channel (Hospital Pharmacies, Retail Pharmacies, Online Pharmacies) and Geography
Global Respiratory Monitoring Devices Market Size Forecast to 2028 - Covid-19 Impact and Global Analysis - By Product (Spirometer, Pulse Oximeter, Peak Flow Meter, and Capnographs), End User (Hospitals, and Home Care) and Geography
Global Respiratory Care Devices Market Size Forecast to 2028 - COVID-19 Impact and Global Analysis By Product {Therapeutic Devices [Positive Airway Pressure (PAP) Devices (CPAP Devices, APAP Devices, and BiPAP Devices), Oxygen Concentrators (Fixed Oxygen Concentrators and Portable Oxygen Concentrators), Ventilators, Inhalers (Metered Dose Inhalers and Dry Powder Inhalers), Nebulizers, Humidifiers, and Others], Monitoring Devices (Pulse Oximeters, Capnography, and Gas Analyzers), Diagnostic Devices (Spirometers, Polysomnography Devices, Peak Flow Meters, and Other Diagnostic Devices), and Consumables & Accessories (Masks, Disposable Resuscitators, Tracheostomy Tubes, Breathing Circuits, and Other Consumables & Accessories)}, Indication [Chronic Obstructive Pulmonary Diseases (COPD), Sleep Apnea, Asthma, Infectious Diseases, and Others], and End User (Hospitals, Home Care, and Ambulatory Care)
About Us:
The Insight Partners is a one stop industry research provider of actionable intelligence. We help our clients in getting solutions to their research requirements through our syndicated and consulting research services. We specialize in industries such as Semiconductor and Electronics, Aerospace and Defense, Automotive and Transportation, Biotechnology, Healthcare IT, Manufacturing and Construction, Medical Device, Technology, Media and Telecommunications, Chemicals and Materials.
Contact Us:
If you have any queries about this report or if you would like further information, please contact us:
Contact Person: Sameer Joshi
E-mail: sales@theinsightpartners.com
Phone: +1-646-491-9876
Press Release: https://www.theinsightpartners.com/pr/respiratory-inhalers-market
